SOPHiA GENETICS SA (SOPH) Form 4 Filings

SOPHiA GENETICS SA Chief Financial Officer George Cardoza reported a small open-market sale of 774 Ordinary Shares. The shares were sold at a weighted average price of $5.3795 per share on June 22, 2026, and he held 310,684 shares afterward.

According to the disclosure, the sale was made to cover tax withholding obligations from restricted stock units that vested on June 18, 2026. The transactions were executed under a pre-established Rule 10b5-1(c) trading plan and are described as non-discretionary.

SOPHiA GENETICS SA President Ross Muken reported an open-market sale of 422 Ordinary Shares at a weighted average price of $5.3803 per share. According to the disclosure, the shares were sold in the open market solely to satisfy tax withholding obligations tied to the vesting of restricted stock units on June 18, 2026, under a pre-established Rule 10b5-1(c) trading plan and were not discretionary trades. Following this small, tax-related transaction, he directly holds 680,489 Ordinary Shares.

SOPHiA GENETICS SA director Troy Cox received new equity awards tied to his board service. He was granted 19,724 restricted stock units, each representing one ordinary share valued at $5.46, bringing his direct holdings to 328,743 ordinary shares.

He also received options to purchase 28,818 ordinary shares at an exercise price of $5.46 per share, expiring on June 18, 2036, increasing his option holdings to 252,809. Both the RSUs and options were granted on June 18, 2026 and vest 100% at the date of the company’s next scheduled annual meeting of shareholders, contingent on his continued service.

SOPHiA GENETICS SA director Kathy L. Hibbs received new equity awards as part of her compensation. She was granted 19,724 restricted stock units, each representing one ordinary share, at a reference price of $5.46 per share. Following this award, she directly holds 109,492 ordinary shares.

She also received options to buy 28,818 ordinary shares at an exercise price of $5.46 per share, expiring on June 18, 2036, bringing her total option holdings to 218,569 share options. Both the RSUs and options were granted on June 18, 2026 and vest 100% at the date of the company’s next scheduled annual meeting of shareholders, subject to her continued service.

SOPHiA GENETICS SA director Vincent Ossipow received equity compensation consisting of restricted stock units and options. On June 18, 2026 he was granted 19,724 RSUs, each representing one ordinary share, and 28,818 share options with a $5.46 exercise price. Both the RSUs and options vest 100% at the date of the company’s next scheduled annual shareholder meeting, subject to his continued service. Following these awards, he directly holds 522,860 ordinary shares and 138,569 options.

SOPHiA GENETICS SA director Jean-Michel Cossery reported receiving new equity awards as part of his compensation. He was granted 19,724 restricted stock units, each representing one ordinary share, and 28,818 share options with a conversion price of $5.46 per share.

Both the RSUs and options were granted on June 18, 2026 and vest 100% at the date of the company’s next scheduled annual meeting of shareholders, subject to his continued service. Following these awards, Cossery directly holds 206,212 ordinary shares and 138,449 options.

SOPHiA GENETICS SA director Didier Hirsch received new equity awards as part of his compensation. He was granted 19,724 Ordinary Shares in the form of restricted stock units valued at $5.46 per share, bringing his direct share holdings to 240,220 Ordinary Shares.

He also received options to buy 28,818 Ordinary Shares at an exercise price of $5.46 per share, with 218,569 options held after the grant. Both the RSUs and the options were granted on June 18, 2026 and vest 100% at the date of the company’s next scheduled annual meeting of shareholders, subject to his continued service.

SOPHiA GENETICS SA Chief Scientific Officer Xu Zhenyu sold 4,000 Ordinary Shares in an open-market transaction. The shares were sold at a weighted average price of $5.0141 per share across multiple trades within a $4.90 to $5.13 range. After this transaction, Xu Zhenyu directly holds 622,280 Ordinary Shares. The sale was executed pursuant to a duly adopted trading plan under Rule 10b5-1(c), indicating the trades were pre-scheduled rather than discretionary.

SOPHiA GENETICS SA Chief Medical Officer Philippe Menu sold 5,000 Ordinary Shares in an open-market transaction at a weighted average price of $4.9504 per share. After this sale, he directly holds 245,780 Ordinary Shares. The trade was executed under a pre-arranged Rule 10b5-1(c) trading plan, meaning it was scheduled in advance rather than timed opportunistically.

SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong sold 8,500 Ordinary Shares in an open-market transaction at a weighted average price of $5.2354 per share. Following the sale, he directly holds 3,620,995 shares.

The sale was made pursuant to a duly adopted trading plan under Rule 10b5-1(c). The shares were sold in multiple trades at prices ranging from $5.13 to $5.42.

SOPHiA GENETICS SA Chief Financial Officer George Cardoza bought 20,000 Ordinary Shares in an open-market purchase at $4.95 per share. After this transaction, he directly holds 311,458 Ordinary Shares. The purchase was made during an open trading window under the company’s insider trading policy.

SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported an open-market sale of 5,000 Ordinary Shares at a weighted average price of $4.9548 per share. The transaction was executed on May 26, 2026 pursuant to a duly adopted Rule 10b5-1(c) trading plan.

After this sale, Menu directly holds 250,780 Ordinary Shares, indicating he retains a substantial equity position in the company. The sale price reflects multiple trades within a range of $4.78 to $5.01 per share, aggregated into the reported weighted average.

SOPHiA GENETICS SA President Ross Muken reported a small open-market sale of 761 Ordinary Shares at a weighted average price of $4.6006 per share. The shares were sold on May 19, 2026 to cover tax withholding obligations from restricted stock units that vested on May 18, 2026.

The filing states these sales were executed under a pre-established Rule 10b5-1(c) trading plan and were not discretionary trades. After the transaction, Muken directly holds 680,911 Ordinary Shares, indicating this was a minor, routine tax-related disposition relative to his overall position.

SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu reported an open-market sale of 608 Ordinary Shares. The shares were sold at a weighted average price of $4.6015 per share on May 19, 2026, to satisfy tax withholding obligations arising from restricted stock units that vested on May 18, 2026.

According to the disclosure, these sales were executed under a pre-established Rule 10b5-1(c) trading plan and are not discretionary trades. Following this transaction, Xu directly holds 626,280 Ordinary Shares.

SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong sold 4,486 Ordinary Shares in an open-market transaction at a weighted average price of $4.6049 per share. The shares were sold on May 19, 2026 to cover tax withholding obligations from restricted stock units that vested on May 18, 2026.

The filing states these sales were executed under a pre-established Rule 10b5-1(c) trading plan and are not discretionary trades. After this transaction, Camblong directly holds 3,629,495 Ordinary Shares.

SOPHiA GENETICS SA’s Chief Medical Officer, Philippe Menu, sold 608 Ordinary Shares of the company on May 19, 2026 at a weighted average price of $4.6059 per share. According to the disclosure, these shares were sold in the open market solely to satisfy tax withholding obligations arising from restricted stock units that vested on May 18, 2026. The transactions were executed under a pre-established Rule 10b5-1(c) trading plan, meaning they were pre-planned and not discretionary. Following this sale, Menu directly holds 255,780 Ordinary Shares.

SOPHiA GENETICS SA Chief Legal Officer Daan Van Well reported an open-market sale of 684 Ordinary Shares at a weighted average price of $4.6042 per share. According to the disclosure, the sale was made to satisfy tax withholding obligations from vesting restricted stock units under a pre-established Rule 10b5-1(c) trading plan and was not discretionary. Following this transaction, Van Well directly holds 345,052 Ordinary Shares.

SOPHiA GENETICS SA’s Chief People Officer, Manuela Valente, reported a small tax-related share sale. On May 19, 2026, she sold 380 Ordinary Shares at a weighted average price of $4.5985 per share, in open-market transactions.

The footnotes explain that these shares were sold solely to cover tax withholding obligations from restricted stock units that vested on May 18, 2026. The transactions were executed under a pre-established Rule 10b5-1(c) trading plan and are not discretionary trades. After the sale, she directly holds 214,691 Ordinary Shares.

SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert reported a small tax-related share sale. He sold 33 ordinary shares in an open-market transaction at $4.5424 per share to satisfy tax obligations from restricted stock units vesting on May 18, 2026. Following this sell-to-cover transaction, he directly holds 148,164 ordinary shares.

SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu sold 4,000 Ordinary Shares in an open-market transaction at a weighted average price of $4.5421 per share. The sale was executed under a pre-established Rule 10b5-1(c) trading plan, and Xu held 626,888 shares directly after the transaction.

SOPHiA GENETICS SA director Kathy L. Hibbs reported an open-market sale of 7,508 Ordinary Shares on May 12, 2026. The shares were sold at a weighted average price of $4.6666 per share, in multiple trades between $4.54 and $4.85.

The transaction was made pursuant to a duly adopted trading plan under Rule 10b5-1(c). Following this sale, Hibbs directly owns 89,768 Ordinary Shares. This represents a partial reduction of her holdings while retaining a substantial remaining position in the company.

SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported an open-market sale of 5,000 Ordinary Shares on May 12, 2026 at a weighted average price of $4.6689 per share. The transaction was made under a pre-arranged Rule 10b5-1(c) trading plan, and Menu now holds 256,388 shares directly.

SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong sold 8,500 ordinary shares in an open-market transaction. The sale took place at a weighted average price of $5.0872 per share under a duly adopted Rule 10b5-1(c) trading plan. Following this transaction, he reports direct ownership of 3,633,981 ordinary shares.

SOPHiA GENETICS SA Chief Medical Officer Philippe Menu executed an open-market sale of 5,000 Ordinary Shares at a weighted average price of $4.8178 per share. Following this transaction, he directly holds 261,388 Ordinary Shares. The sale was made under a duly adopted Rule 10b5-1(c) trading plan.

SOPHiA GENETICS SA Chief People Officer Manuela Valente sold 380 ordinary shares in an open-market transaction. The shares were sold at a weighted average price of $5.2031 per share on April 20, 2026, and she held 215,071 shares afterward.

According to the disclosure, the sale was made solely to cover tax withholding obligations tied to restricted stock units that vested on April 18, 2026. The transactions were executed under a pre-established Rule 10b5-1(c) trading plan, meaning they were pre-planned and not discretionary market-timing trades.

SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu reported an open-market sale of 608 Ordinary Shares at a weighted average price of $5.2053 per share. According to the disclosure, the shares were sold to satisfy tax withholding obligations tied to restricted stock units that vested on April 18, 2026.

The transactions were executed under a pre-established Rule 10b5-1(c) trading plan and are described as non-discretionary. Following these sales, Xu directly holds 630,888 Ordinary Shares.

SOPHiA GENETICS SA Chief Legal Officer Van Well Daan sold 684 Ordinary Shares in an open-market transaction at a weighted average price of $5.1963 per share. The sale occurred on April 20, 2026 and was executed to cover tax withholding obligations from restricted stock units that vested on April 18, 2026.

The filing states that these transactions were carried out under a pre-established Rule 10b5-1(c) trading plan and are not discretionary trades. After the sale, Van Well Daan directly owned 345,736 Ordinary Shares.

SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong reported an open-market sale of 4,486 Ordinary Shares. The shares were sold on April 20, 2026 at a weighted average price of $5.205 per share, in multiple trades ranging from $5.08 to $5.29.

The sale was made to satisfy tax withholding obligations arising from restricted stock units that vested on April 18, 2026, under a pre-established Rule 10b5-1(c) trading plan and is described as non-discretionary. After the transaction, Camblong directly holds 3,642,481 Ordinary Shares.

SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported a small open-market sale of 608 ordinary shares of SOPH. The shares were sold at a weighted average price of $5.2002 per share and were made to satisfy tax withholding obligations tied to restricted stock units that vested on April 18, 2026.

These transactions were executed under a pre-established Rule 10b5-1(c) trading plan and are not discretionary trades. After the sale, Menu directly holds 266,388 ordinary shares, indicating that the transaction affected only a very small portion of his overall position.

SOPHiA GENETICS SA President Ross Muken sold 760 Ordinary Shares in an open-market transaction. The shares were sold at a weighted average price of $5.2039 per share to cover tax withholding obligations from restricted stock units that vested on April 18, 2026.

The filing states these sales were made under a pre-established Rule 10b5-1(c) trading plan and are not discretionary trades. After this tax-related sale, Muken directly holds 681,672 Ordinary Shares, indicating the transaction is small relative to his reported position.

SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert reported a small, non-discretionary share sale tied to taxes. On April 18, 2026, 33 Ordinary Shares were sold in the open market at an average price of $5.0816 per share to satisfy tax obligations from vesting restricted stock units. After this sell-to-cover transaction, he directly holds 148,197 Ordinary Shares.

SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu reported an open-market sale of 600 ordinary shares on April 14, 2026 at a weighted average price of $4.9663 per share. The sale was executed under a pre-arranged Rule 10b5-1(c) trading plan, and Xu continued to hold 631,496 ordinary shares directly after the transaction.

SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong reported routine share sales tied to tax obligations. On April 14 and 15, 2026, he sold a total of 60,602 ordinary shares in open-market transactions at weighted average prices of $4.9580 and $5.0021 per share. The filing states these sales were executed to satisfy tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026, under a pre-established Rule 10b5-1(c) trading plan, meaning they were not discretionary trades. After these transactions, he continues to hold 3,646,967 ordinary shares directly.

Chief Medical Officer Philippe Menu of SOPHiA GENETICS SA sold 1,600 ordinary shares in an open-market transaction on April 14, 2026. The shares were sold at a weighted average price of $4.9581 per share under a pre-established Rule 10b5-1(c) trading plan.

Following this sale, Menu directly holds 266,996 ordinary shares. The transaction was executed through multiple trades at prices ranging from $4.78 to $5.16 per share.

SOPHiA GENETICS SA President Ross Muken completed an open-market sale of 2,800 Ordinary Shares at a weighted average price of $4.9597 per share. After this transaction, he directly holds 682,432 shares. The sale was made to cover tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026 and was executed under a pre-established Rule 10b5-1(c) trading plan, meaning it did not represent a discretionary trade.

SOPHiA GENETICS SA Chief Legal Officer Daan Van Well reported selling 2,400 Ordinary Shares of SOPH on April 10, 2026 at a weighted average price of $4.6672 per share. The footnotes state these shares were sold in the open market solely to satisfy tax withholding obligations from restricted stock units vesting on April 2 and 3, 2026.

The sales were executed under a pre-established Rule 10b5-1(c) trading plan and are described as non-discretionary. After the transaction, Van Well directly holds 346,420 Ordinary Shares, indicating he retained a substantial equity position in the company.

SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu reported open‑market sales of 8,120 Ordinary Shares of SOPH. The shares were sold on April 10 and April 13, 2026 at weighted average prices around $4.68–$4.76 per share.

According to the disclosure, these sales were made to satisfy tax withholding obligations tied to restricted stock units that vested on April 2 and 3, 2026, and were carried out under a pre‑established Rule 10b5‑1(c) trading plan. Following the transactions, Xu continues to hold 632,096 Ordinary Shares directly.

SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong reported open-market sales of 16,631 ordinary shares of SOPH. The shares were sold on April 10 and 13, 2026 at weighted average prices around $4.72–$4.76 per share.

Footnotes state these transactions were effected under a pre-established Rule 10b5-1(c) trading plan to satisfy tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026, and are not discretionary trades. After these sales, Camblong continues to hold 3,707,569 ordinary shares directly.

SOPHiA GENETICS SA President Ross Muken reported two small open-market sales of Ordinary Shares to cover taxes from equity vesting. On April 10 and 13, 2026, he sold a total of 8,129 shares at weighted average prices around $4.69–$4.77 per share. A footnote explains these transactions were made to satisfy tax withholding obligations arising from restricted stock units that vested on April 2 and 3, 2026, and were executed under a pre-established Rule 10b5-1(c) trading plan, meaning they were not discretionary trades. Following the sales, he continues to hold 685,232 Ordinary Shares directly.

SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported small open-market sales of Ordinary Shares mainly to cover taxes from recent equity vesting. Across three transactions on April 10 and April 13, 2026, he sold a total of 8,125 shares at weighted-average prices around $4.68–$4.76 per share. The filing states these sales were made to satisfy tax withholding obligations tied to restricted stock units that vested on April 2 and 3, 2026 and were executed under a pre-established Rule 10b5-1(c) trading plan. After these transactions, Menu continues to hold 268,596 Ordinary Shares directly.

SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong reported routine tax-related share sales. He sold 2,800 Ordinary Shares on April 8 at a weighted average of $4.8404 and 1,950 shares on April 9 at a weighted average of $4.7404 in open‑market transactions.

Footnotes state these sales were made solely to satisfy tax withholding obligations tied to restricted stock units that vested on April 2 and 3, 2026, under a pre‑established Rule 10b5‑1 trading plan. After these transactions, he continues to hold 3,724,200 Ordinary Shares directly.

SOPHiA GENETICS SA president Ross Muken reported open-market sales of ordinary shares primarily to cover taxes from equity compensation. On April 8 and 9, 2026, he sold a total of 4,736 shares at weighted average prices of about $4.84 and $4.74 per share. The filing states these trades were executed under a pre-established Rule 10b5-1 trading plan and were made to satisfy tax withholding obligations tied to restricted stock units that vested earlier in April. After these sales, Muken still directly holds 693,361 ordinary shares, indicating the transactions represent a small portion of his overall position.

SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu sold 4,736 Ordinary Shares of SOPH in open-market transactions. The sales occurred on April 8 and 9, 2026 at weighted average prices of about $4.84 and $4.74 per share.

According to the disclosure, these shares were sold to cover tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026. The transactions were executed under a pre-established Rule 10b5-1 trading plan and are described as non-discretionary. After the sales, Xu directly held 640,216 Ordinary Shares.

SOPHiA GENETICS SA Chief Medical Officer Philippe Menu disposed of 4,731 Ordinary Shares in open-market sales tied to tax obligations. On April 8, he sold 2,800 shares at a weighted average of $4.8370, and on April 9 he sold 1,931 shares at a weighted average of $4.7393.

The footnotes state these sales were made to satisfy tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026 and were executed under a pre-established Rule 10b5-1 trading plan, meaning they were not discretionary trades. After these transactions, Menu directly holds 276,721 Ordinary Shares.

SOPHiA GENETICS SA Chief People Officer Manuela Valente reported an open-market sale of 3,824 Ordinary Shares on April 8, 2026 at a weighted average price of $4.849 per share. According to the disclosure, the shares were sold to satisfy tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026.

The filing states these sales were executed under a pre-established Rule 10b5-1 trading plan and are described as non-discretionary. After this transaction, Valente directly holds 215,451 Ordinary Shares of SOPHiA GENETICS SA.

SOPHiA GENETICS SA Chief Legal Officer Daan Van Well reported routine tax-related share sales. He sold a total of 4,849 Ordinary Shares in open-market transactions on April 8 and 9, 2026 at weighted average prices of $4.8452 and $4.7406 per share. According to the disclosure, these sales were made to satisfy tax withholding obligations from the vesting of restricted stock units under a pre-established Rule 10b5-1 trading plan and are not discretionary trades. After these transactions, he continues to hold 348,820 Ordinary Shares directly.

SOPHiA GENETICS SA Chief Financial Officer George Cardoza sold 1,403 ordinary shares of SOPH on April 8, 2026. The shares were sold in open-market transactions at a weighted average price of about $4.85 per share to cover tax withholding from recently vested restricted stock units.

According to the disclosure, these sales were made under a pre-established Rule 10b5-1 trading plan and are described as non-discretionary. After these transactions, Cardoza directly holds 291,458 ordinary shares, indicating the sale represents a small portion of his overall position.

SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported routine share sales tied to equity compensation taxes. He sold a total of 5,100 Ordinary Shares in open-market transactions on April 6 and 7, 2026 at weighted average prices of $4.8505 and $4.8653 per share.

According to the disclosure, these sales were made to satisfy tax withholding obligations arising from restricted stock unit vesting on April 2 and 3, 2026 and were executed under a pre-established Rule 10b5-1 trading plan, rather than as discretionary trades. Following the sales, he directly holds 281,452 Ordinary Shares.

SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert sold 624 Ordinary Shares of SOPH in open-market transactions. The sales occurred on April 6, 2026 at prices around $4.86 per share and were executed solely to cover tax obligations from recently vested restricted stock units.

After these tax-related sales, Puylaert directly holds 148,230 Ordinary Shares, indicating that only a very small portion of his equity position was used for the "sell to cover" transactions, which the company describes as non-discretionary rather than voluntary market trades.